More clinical trials are open than ever before. Yet, the costs are soaring, the research workforce is shrinking, enrollment rates are falling, and patients are waiting in hope for new treatments that may never arrive. Without urgent reform, the clinical trial enterprise as we know it cannot continue on its current trajectory.

So, what does the future hold for clinical trials? And is there a better way forward? In this fireside chat, Kent Thoelke, CEO of Paradigm Health and Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy (PICI), discuss the clinical trial ecosystem and the case for urgent reform.